CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 20-154/S-029, S-030
20-155/S-021
20-156/S-022

CHEMISTRY REVIEW

SUPPLEMENTAL NDA CHEMIST'S REVIEW	1. ORGANIZATION HFD-530	2. NDA NUMBER 20-154

3. NAME AND ADDRESS OF APPLICANT *(City and State)*
Bristol-Myers Squibb Company
P.O. Box 5400
Princeton, NJ 08543-5400

4. AF NUMBER

5. SUPPLEMENT(S)

NUMBER(S)	DATE(S)
SE2029, SCF030	4/29/99

6. NAME OF DRUG
VIDEX[R]

7. NONPROPRIETARY NAME
Didanosine

8. SUPPLEMENT(S) PROVIDES FOR:
A 200 mg strength of Videx Chewable/Dispersible Buffered Tablets and a change in dosing to once-daily administration in combination therapy to treat HIV-infected patients

9. AMENDMENTS AND OTHER *(Reports, etc)* **DATES**
8/19/99

10. PHARMACOLOGICAL CATEGORY
Antiviral

11. HOW DISPENSED
|X| Rx | | OTC

12. RELATED IND/NDA/DMF(S)

13. DOSAGE FORM(S)
Chewable/Dispersible Buffered Tablets (reduced mass)

14. POTENCY(IES)
200 mg

15. CHEMICAL NAME AND STRUCTURE

2', 3'-dideoxyinosine

16. RECORDS AND REPORTS
Curren
| | Yes | | No
Reviewed
| | Yes | | No

17. COMMENTS

The 4/29/99 submission contains clinical data to support approval of once-daily dosing of Videx in combination therapy to treat HIV-infected patients (SE2029), as well as CMC and pharmacokinetic data to support registration of a new 200 mg strength of the currently marketed reduced mass Videx Tablets (SCF030). The 200 mg tablets contains the same ingredients as the currently marketed 25, 50, 100, and 150 mg tablet strengths differing only in the amounts of excipients which are adjusted for the increased quantity of ddI. The antacid system which is designed to neutralize stomach acid and protect ddI from acid degradation remains identical for all strengths. The CMC section of this application contains the following: (ii) DP specifications and analytical methods, including validation data, (iii) batch analysis (iv) 18 months stability data, and (v) container labels.

(a) Manufacturing and packaging of the 200 mg tablets remained unchanged from the currently approved tablet strengths. Executed batch record for #8MEH130 used in the dose proportional study was found acceptable. Master Batch Record was found acceptable.
(b) DP specifications remained unchanged. Analytical methods for ddI, hypoxanthine, and dissolution were revised and validated. The methods were found acceptable.
(c) Batch analysis of the three registration lots showed that all drug substance and drug product lots met the current DS and DP specifications.
(d) Eighteen months stability data showed the product was stable at 30° C/60%RH and 25° C/60%RH over the test period. Regression curve showed the degradation for the 25 mg, 150 mg and 200 mg strengths were comparable. Based on these data, a 24 months expiration dating period is granted to the 200 mg Videx tablets.
(e) Container label was found acceptable. The chemistry section of the package insert was found acceptable.

18. CONCLUSIONS AND RECOMMENDATIONS
Information submitted was found acceptable. From a CMC standpoint, this supplement is **approved.**

19. REVIEWER		
NAME: Ko-Yu Lo, Ph.D.	SIGNATURE: /S/	DATE COMPLETED: 9/9/99
20. CONCURRENCE: HFD-530/SMiller	/S/	9/23/99

DISTRIBUTION						
	X	Original Jacket	X	Division File	X	KLo
	X	SMiller	X	CChen		DSillivan

ATTACHMENT 2

9 page(s) have been removed because it contains trade secret and/or confidential information that is not disclosable.